Business Wire

Q4 Inc. Releases Next Generation Investor Conference Features for its Rapidly Growing Investment Banking Client Base

9.12.2021 17:00:00 EET | Business Wire | Press release

Share

Q4 Inc. (TSX: QFOR) (“Q4" or “the Company”), a leading capital markets communications platform, today announced the release of a suite of new features for its Capital Markets Event (“CME”) platform, launched earlier this year, and designed to provide virtual and in-person events for investment banking hosted investor conferences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005633/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Branded Event Registration (Graphic: Business Wire)

Starting in 2020, Q4 has experienced unprecedented demand from investment banks to create, host and deliver investor conferences for their buy-side clients. Since that time, Q4 has hosted thousands of market participants across investor conferences, reverse roadshows and corporate investor days and has established the bar by which all other capital markets and financial service events are measured. Building on its rapidly expanding footprint in the investment banking market, Q4 continues to enhance the CME platform in its partnership with corporate access teams at the world’s leading investment banks.

New capabilities recently added include sophisticated event registration, easy scheduling for meetings of all sizes, whether they are 1:1, 2:1 or larger group meetings, and meeting management data and analytics to assist corporate access teams successfully envision, plan and execute these critical events. These new features are embedded within Q4’s event platform, as well as API integrated into Zoom, Microsoft Teams and other technologies, delivering a seamless conference experience for all participants.

Specifically, these new features provide new registration functionality, which allows corporate and investor participants to submit their availability, and allows investors to indicate which corporate issuers they are interested in meeting with in priority order and preference for 1:1, 2:1 or a larger group meeting. This information is directly funneled to the internal scheduling tool, which makes scheduling significantly easier and updates automatically as participant availability changes.

Additionally, the Platform has new features that allow for meeting details to be easily added, edited and made available to all participants so that everyone is easily informed about the type of meeting, attendee information, and easy links for meeting access.

Finally, this upgrade provides critical data around scheduling as well as session and meeting attendance, helping corporate access teams determine which corporate issuers and investors may need additional meetings to enrich their experience, and require priority focus.

“We launched our Capital Markets Events (CME) platform with the vision of connecting all capital markets participants in their discovery, communications and engagement with each other,” said Darrell Heaps, CEO of Q4. “We are excited to enhance the capabilities of our platform, and deliver an elevated experience for our investment bank customers. We will continue to add features to our rapidly evolving solution, as we lead the digital transformation of corporate access engagements that connect all sides of the capital markets.”

To learn more about the Q4 CME platform, click here.

About Q4, Inc.

Q4 Inc. (Q4), is a leading capital markets communications platform that is transforming the way publicly traded companies, investors, and investment banks make decisions to efficiently discover, communicate, and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets customer relationship management solution, and shareholder and market analytics tools. The firm is a trusted partner to over 2,600 public companies as well as top tier investment banks. Q4 is based in Toronto, with offices in New York and London.

To learn more, visit: www.q4inc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries:
Karen Greene media@q4inc.com

IR Inquiries:
Matt Tractenberg ir@q4inc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye